The medical technology company will discuss its neurological monitoring platform at an upcoming industry event focused on diagnostics and digital health
Sunnyvale, California, 29 October 2026 - Ceribell, a medical technology company focused on neurological care, has announced its participation in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The event will allow the company to discuss its work in brain monitoring and the role of technology in helping healthcare professionals identify serious neurological conditions.
Scott Blumberg, Chief Financial Officer of Ceribell, is scheduled to participate in a fireside chat on November 11, 2026, in connection with the forum in New York City. The session is scheduled for 10 a.m. Eastern Standard Time. A live webcast and an archived recording will be available through the company’s investor relations website.
The forum brings together participants from the medical technology, diagnostics, and digital health sectors. Such events provide a platform for companies to share business developments, discuss industry priorities, and explain how their technologies fit into the changing healthcare landscape.
Ceribell develops technology designed to support the diagnosis and monitoring of patients with serious neurological conditions. Its core offering, the Ceribell System, is a portable electroencephalography (EEG) platform built for use in acute care settings, including hospital emergency departments and intensive care units.
EEG is a test that records electrical activity in the brain. It helps clinicians assess brain function and investigate conditions such as seizures. However, traditional EEG procedures can require specialized equipment and trained personnel, which may limit how quickly monitoring can begin in some clinical settings.
Ceribell aims to address these challenges through portable hardware and artificial intelligence-powered algorithms. Its system is designed to be deployed quickly, allowing healthcare teams to monitor brain activity and identify suspected seizure activity without relying entirely on conventional EEG workflows. The system has received US Food and Drug Administration 510(k) clearance for specified uses, including detecting suspected seizure activity and monitoring delirium in acute care settings.
The company has continued to expand the capabilities of its platform. In September 2026, Ceribell announced additional FDA clearance for software features that provide quantitative EEG trends and amplitude-integrated EEG analysis. These features are intended to help clinicians interpret changes in brain activity more efficiently across different patient groups and care settings.
The growing use of artificial intelligence in healthcare is creating opportunities to make clinical information easier to interpret and use. In neurological care, where timely assessment can influence treatment decisions, technology that supports faster access to brain monitoring may be particularly valuable.
Ceribell’s participation in the forum comes as healthcare organizations continue to explore digital health solutions that can support clinical workflows and improve access to diagnostic information. The upcoming discussion will provide an opportunity for the company to outline its business and technology developments to investors and other industry participants.